Samyukta Mullangi, Medical Oncologist at Tennessee Oncology and Senior Medical Director at Thyme Care, shared a post on LinkedIn:
“Got to speak about cancer value-based care (a favorite topic) and discuss the unique role that Thyme Care plays in the payer-provider relationship for Penn Medicine Princeton Health grand rounds today.
I cover
- the rationale for value-based care efforts in oncology (suboptimal patient journey, high rates of acute care utilization, expensive episodes of care, high rates of chemo at end of life)
- the complexity of VBC in oncology (disease heterogeneity, lack of clinical equipoise between therapeutic switches, reliance on case mix)
- he history of CMMI efforts in this space – OCM and EOM, and reviews of each
- where is all this going really!? (my favorite part – so fun to muse)
- the interaction between drug pricing programs and VBC
- the rationale and business model of a value-based care enabler like Thyme Care
- an overview of how we operationalize one of our signature value-based drug prescribing interventions (shows the different levers we deploy, and the overall complexity involved)
TY TY Ramy Sedhom for the nom!”
More posts featuring Samyukta Mullangi on OncoDaily.